Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Laboratory Biomarker Analysis

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00079131Phase 2Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

NCT00068783Phase 2Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis2
  • Imatinib Mesylate1
  • Oblimersen Sodium1
  • Pharmacological Study1

Active Sponsors

  • National Cancer Institute (NCI)2

Top Investigators

  • Ki Chung1

    Memorial Sloan Kettering Cancer Center

Related Conditions

  • Stage Iii Neuroendocrine Carcinoma Of The Skin2
  • Recurrent Neuroendocrine Carcinoma Of The Skin2
  • Stage I Neuroendocrine Carcinoma Of The Skin1
  • Stage Iv Neuroendocrine Carcinoma Of The Skin1

Activity Timeline